...Sheng-Chu Chi; Chang-Chi Weng; Shih-Jen Chen; Tai-Chi Lin; Yu-Bai Chou; De-Kuang Hwang Introduction: Anti-vascular endothelial growth factor (VEGF) treatment stands as the primary approach for neovascular age-related macular degeneration (nAMD). Faricimab has recently emerged as a novel anti-VEGF...

... of SMH secondary to neovascular age-related macular degeneration (nAMD) or polypoidal choroidal vasculopathy (PCV) from May 1, 2015, to October 31, 2022. Medical records were reviewed for diagnosis, logMAR visual acuity (VA), central subfield thickness (CST), and postoperative displacement rates...

...Samuel D Relton; Gloria C Chi; Andrew J Lotery; Robert M West; Martin McKibbin; Real-world AMD treatment outcomes EMR User Group Aims: The aim of the study was to investigate non-persistence with treatment for neovascular age-related macular degeneration (NvAMD) before day 720 (24 months) after...

...Michele Cavalleri; Beatrice Tombolini; Riccardo Sacconi; Gianpaolo Gatta; Renato Valeri; Francesco Bandello; Giuseppe Querques Introduction: To analyze visual and anatomical outcomes after switch to intravitreal brolucizumab therapy in eyes affected by neovascular age-related macular degeneration...

... Sagong; Se Joon Woo Introduction: The aim of the study was to determine the short-term real-world safety and efficacy of intravitreal brolucizumab injections in Korean patients with neovascular age-related macular degeneration (nAMD). Methods: This multicenter retrospective study involved 294 eyes...

... in detecting retinal fluid in spectral-domain OCT volume scans from a large cohort of patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Methods: A total of 3,981 OCT volumes from 374 patients with AMD and 11,501 OCT volumes from 811 patients with DME were...

...Junki Hoshino; Hidetaka Matsumoto; Ryo Mukai; Kosuke Nakamura; Hideo Akiyama Introduction: The purpose of this study was to evaluate the outcomes of loading-phase treatment with intravitreal aflibercept (IVA) or brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration...

... endothelial growth factor Treatment Response Prediction Neovascular age-related macular degeneration Age-related macular degeneration (AMD) is the leading cause of blindness in elderly people in developed countries [1]. AMD prevalence worldwide, within the age of 55–85 years, is estimated...

...Terhi Ollila; Juuso Silvennoinen; Ashwini Joshi; Jia Liu; Sangita Kulathinal; Ilkka Immonen Purpose: We aimed to study the regional detailed visual outcome and treatment discontinuation of neovascular age-related macular degeneration (nAMD). Methods: Clinical records of 110 patients treated...

... factor Brolucizumab Fixed dosing Neovascular age-related macular degeneration Anti-vascular endothelial growth factor (anti-VEGF) therapy is the gold standard treatment for neovascular age-related macular degeneration (nAMD), with proven efficacy in visual and anatomical outcomes in clinical...

... , Boyer DS , Kaiser PK , Chung CY , . Ranibizumab for neovascular age-related macular degeneration . N Engl J Med . 2006 Oct ; 355 ( 14 ): 1419 – 31 . 2. Heier JS , Brown DM , Chong V , Korobelnik JF , Kaiser PK , Nguyen QD , . Intravitreal...

... in patients with neovascular age-related macular degeneration who remain on T&E and those switched from once-monthly (OM) dosing to T&E (OM-T&E). Methods: In this 12-month extension of the 2-year CANTREAT study, patients received intravitreal ranibizumab 0.5 mg in a T&E regimen. Main outcome...

... review and meta-analysis . Lancet Glob Health . 2014 Feb ; 2 ( 2 ): e106 – 16 . 2. Schmidt-Erfurth   U , Chong   V , Loewenstein   A , Larsen   M , Souied   E , Schlingemann   R ,   Guidelines for the management of neovascular age-related macular degeneration by the European...

...Costanza Barresi; Enrico Borrelli; Federico Fantaguzzi; Domenico Grosso; Riccardo Sacconi; Francesco Bandello; Giuseppe Querques Background: Neovascular age-related macular degeneration (AMD) represents a leading cause of vision loss in older subjects. The introduction of anti-vascular endothelial...

... retina experts, have been developed to assist both retina specialists and general ophthalmologists in the management of vision-threatening neovascular age-related macular degeneration (nAMD). The recommendations are based on published evidence as well as collective experience and expertise in routine...

... Neovascular age-related macular degeneration Artefacts 1 10 2020 6 06 2021 30 7 2021 [email protected] © 2021 S. Karger AG, Basel 2021 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other...

...) on complement activation in patients with neovascular age-related macular degeneration (nAMD) under ongoing treatment. Methods: In this prospective, single-center, controlled, open-label investigator-initiated trial, eligible nAMD patients were randomized at a ratio of 1:1 in 2 groups: those with and without...

...Anniken Burés Jelstrup; Esther Pomares; Rafael Navarro; on behalf of the BIOIMAGE Study Group Purpose: To identify the genetic variants of the vascular endothelial growth factor (VEGF) pathway genes and other genes associated with neovascular age-related macular degeneration (nAMD) as possible...

... challenge for healthcare providers who must meet the logistical and economic burden of providing adequate treatment to all AMD patients [ 3 ]. Anti-VEGF Neovascular age-related macular degeneration Treatment burden Undertreatment Anti-VEGF therapy has revolutionized visual outcomes in nAMD...

...Andrew C. Browning; Jill M. O’Brien; Rute V. Vieira; Rajen Gupta; Kapka Nenova Introduction: Retinal angiomatous proliferation (RAP) is a subtype of neovascular age-related macular degeneration (nAMD). Untreated, the lesions are thought to be aggressive and lead to a poor visual outcome. Despite...